Advertisement

Role of Omega-3 Fatty Acids in Cardiovascular Disorders

  • Soumia Peter
  • Jubbin Jagan Jacob
Chapter

Abstract

Since the 1970s, there has been mounting evidence regarding the crucial role played by omega-3 fatty acids in the primary and secondary preventions of cardiovascular (CV) events. The omega-3 fatty acids of relevance are the eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that are obtained from fish oils, and alpha-linolenic acid (ALA) from plant sources such as flaxseed oil. Research has proven their cardio-protective actions improve endothelial function, anti-inflammatory actions, inhibition of platelet aggregation, and regulation of influx and efflux of sodium and calcium channels and triglyceride lowering effects. They also play a role in prevention of heart failure by enhancement of cardiac remodelling. In this review, we discuss the CV benefits of omega-3 fatty acids, detailing their potential mechanisms of action in the prevention of CV mortality and sudden cardiac death. We have outlined the dosages recommended for therapy and have mentioned the reported side effects while presenting a collective overview of the recent randomized controlled trials and analysis on this subject, highlighting both results and limitations.

Keywords

Omega-3 fatty acids Eicosapentaenoic acid (EPA) Docosahexaenoic acid (DHA) Cardiovascular diseases (CVD) 

References

  1. 1.
    Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312:1205–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–57.PubMedCrossRefGoogle Scholar
  3. 3.
    Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis. 2013;230:381–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Pan A, Chen M, Chowdhury R, Wu JH, Sun Q, Campos H, et al. Alpha-linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96:1262–73.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Welch AA, Shakya-Shrestha S, Lentjes MA, Wareham NJ, Khaw KT. Dietary intake and status of n-3 polyunsaturated fatty acids in a population of fish-eating and non-fish-eating meat-eaters, vegetarians, and vegans and the product-precursor ratio [corrected] of alpha-linolenic acid to long-chain n-3 polyunsaturated fatty acids: results from the EPIC-Norfolk cohort. Am J Clin Nutr. 2010;92:1040–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Harris WS. Fish oil supplementation: evidence for health benefits. Clevel Clin J Med. 2004;71:208–10.CrossRefGoogle Scholar
  8. 8.
    Flock MR, Harris WS, Kris-Etherton PM. Long-chain omega-3 fatty acids: time to establish a dietary reference intake. Nutr Rev. 2013;71:692–707.PubMedCrossRefGoogle Scholar
  9. 9.
    Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol. 2006;1(2):182–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Hussein N, Ah-Sing E, Wilkinson P, Leach C, Griffin BA, Millward DJ. Long-chain conversion of [13C] linoleic acid and alpha-linolenic acid in response to marked changes in their dietary intake in men. J Lipid Res. 2005;46:269–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Pereira SL, Leonard AE, Huang Y-S, Chuang L-T, Mukerji P. Identification of two novel microalgal enzymes involved in the conversion of the ω3-fatty acid, eicosapentaenoic acid, into docosahexaenoic acid. Biochem J. 2004;384:357–66.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    MaraiI I., Massalha S. Effect of omega-3 polyunsaturated fatty acids and vitamin D on cardiovascular diseases. IMAJ. 2014;16:117–21.Google Scholar
  13. 13.
    Grimsgaard S, Bønaa KH, Hansen JB, Myhre ESP. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr. 1998;68(1):52–9.PubMedGoogle Scholar
  14. 14.
    Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease. Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–67.PubMedCrossRefGoogle Scholar
  15. 15.
    Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012;107:S201–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Koh KK, Han SH, Oh PC, Shin EK, Quon MJ. Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis. 2010;209:307–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197:12–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17:387–93.PubMedCrossRefGoogle Scholar
  20. 20.
    Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes. 2005;54:1907–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr. 2001;131:1129–32.PubMedGoogle Scholar
  22. 22.
    Rivellese AA, Maffettone A, Iovine C, Di Marino L, Annuzzi G, Mancini M, et al. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care. 1996;19:1207–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Saraswathi V, Morrow JD, Hasty AH. Dietary fish oil exerts hypolipidemic effects in lean and insulin sensitizing effects in obese LDLR–/– mice. J Nutr. 2009;139:2380–6.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Jump DB. Fatty acid regulation of hepatic lipid metabolism. Curr Opin Clin Nutr Metab Care. 2011;14:115–20.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Samuel S, Peskin B, Arondekar B, Alperin P, Johnson S, Blumenfeld I, et al. Estimating health and economic benefits from using prescription omega-3 fatty acids in patients with severe hypertriglyceridemia. Am J Cardiol. 2011;108:691–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Raitt MH, Connor WE, Morris C, Kron J, Halperin B, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293:2884–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 1993;88:2953–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Campbell RW, Murray A, Julian DG. Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study. Br Heart J. 1981;46:351–7.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107:2646–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation. 1999;99:2452–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Christensen JH, Riahi S, Schmidt EB, Molgaard H, Kirstein PA, Heath F, et al. n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillators. Europace. 2005;7:338–44.PubMedCrossRefGoogle Scholar
  32. 32.
    Schrepf R, Limmert T, Weber PC, Theisen K, Sellmayer A. Immediate effects of n-3 fatty acid infusion on the induction of sustained ventricular tachycardia. Lancet. 2004;363:1441–2.PubMedCrossRefGoogle Scholar
  33. 33.
    Verkerk AO, van Ginneken AC, Berecki G, Den Ruijter HM, Schumacher CA, Veldkamp MW, et al. Incorporated sarcolemmal fish oil fatty acids shorten pig ventricular action potentials. Cardiovasc Res. 2006;70:509–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Coronel R, Wilms-Schopman FJ, Den Ruijter HM, Belterman CN, Schumacher CA, Opthof T, et al. Dietary n-3 fatty acids promote arrhythmias during acute regional myocardial ischemia in isolated pig hearts. Cardiovasc Res. 2007;73:386–94.PubMedCrossRefGoogle Scholar
  35. 35.
    Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids review. Lancet. 2010;375:540–50.CrossRefGoogle Scholar
  36. 36.
    Leifert WR, Jahangiri A, McMurchie EJ. Membrane fluidity changes are associated with the antiarrhythmic effects of docosahexaenoic acid in adult rat cardiomyocytes. J Nutr Biochem. 2000;11:38–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;344:757–61.CrossRefGoogle Scholar
  38. 38.
    GISSI-Prevenzione Investigators (GruppoItaliano per lo Studio dellaSopravvivenza nell’Infartomiocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447–55.Google Scholar
  39. 39.
    Nodari S, Metra M, Milesi G, Manerba A, Cesana BM, Gheorghiade M, et al. The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther. 2009;23:5–15.PubMedCrossRefGoogle Scholar
  40. 40.
    Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol. 2008;52:306–13.PubMedCrossRefGoogle Scholar
  41. 41.
    Aviles RJ, Martin DO, pperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Rees D, Miles EA, Banerjee T. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr. 2006;83:331–42.PubMedGoogle Scholar
  43. 43.
    Serhan CN, Clish CB, Brannon J, Colgan SP, Gronert K, Chiang N. Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J Physiol Pharmacol. 2000;51:643–54.PubMedGoogle Scholar
  44. 44.
    Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197–204.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70(3):560S–9S.PubMedGoogle Scholar
  47. 47.
    Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26.PubMedCrossRefGoogle Scholar
  48. 48.
    MacLean CH, Mojica WA, Morton SC, Pencharz J, Garden RH, Tu W, et al. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid Rep Technol Assess (Summ). 2004;89:1–4.Google Scholar
  49. 49.
    Broughton KS, Johnson CS, Pace BK, Liebman M, Kleppinger KM. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. Am J Clin Nutr. 1997;65:1011–7.PubMedGoogle Scholar
  50. 50.
    Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009;(1):CD006320.Google Scholar
  51. 51.
    Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n-3-omega-fatty acid: an open trial. J Clin Gastroenterol. 1990;12:157–61.PubMedCrossRefGoogle Scholar
  52. 52.
    Mayser P, Mrowietz U, Arenberger P, Bartak P, Buchvald J, Christophers E, et al. ω-3 Fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol. 1998;38:539–47.PubMedCrossRefGoogle Scholar
  53. 53.
    Goodfellow J, Bellamy MF, Ramsey MW, Jones CJH, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol. 2000;35(2):265–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Schiano V, Laurenzano E, Brevetti G, Isabel D, Malo J, Lanero S, et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr. 2008;27(2):241–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Haberka M, Mizia-Stec K, Mizia M, Janowska J, Gleszczyk K, Chmiel A, et al. N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through no inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction. Clin Nutr. 2010;30(1):79–85.PubMedCrossRefGoogle Scholar
  56. 56.
    Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J. 2012;59(4):297–304.PubMedCrossRefGoogle Scholar
  57. 57.
    McVeigh GE, Brennan GM, Cohn JN, Finkelstein SM, Hayes RJ, Johnston GD. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb. 1994;14(9):1425–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Casos K, Zaragoza MC, Zarkovic N, Zarkovic K, Andrisic L, et al. A fish-oil-rich diet reduces vascular oxidative stress in ApoE(–/–) mice. Free Radical Res. 2010;44(7):821–9.CrossRefGoogle Scholar
  59. 59.
    Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006;98:39i–49i.PubMedCrossRefGoogle Scholar
  60. 60.
    de Roos B, Mavrommatis Y, Brouwer IA. Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol. 2009;158:413–28.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Mavrommatis Y, Ross K, Rucklidge G, Reid M, Duncan G, Gordon MJ, et al. Intervention with fish oil, but not with docosahexaenoic acid, results in lower levels of hepatic soluble epoxide hydrolase with time in apoE knockout mice. Br J Nutr. 2010;103(1):16–24.PubMedCrossRefGoogle Scholar
  62. 62.
    Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993;88:523–33.PubMedCrossRefGoogle Scholar
  63. 63.
    McLennan PL. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids. 2001;36:S111–4.PubMedCrossRefGoogle Scholar
  64. 64.
    Billman GE, Kang JX, Leaf A. Prevention of ischemia-induced cardiac sudden death by n-3 polyunsaturated fatty acids in dogs. Lipids. 1997;32:1161–8.PubMedCrossRefGoogle Scholar
  65. 65.
    O’Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol. 2006;97:1127–30.PubMedCrossRefGoogle Scholar
  66. 66.
    Mozaffarian D, Gottdiener JS, Siscovick DS. Intake of tuna or other broiled or baked fish versus fried fish and cardiac structure, function, and hemodynamics. Am J Cardiol. 2006;97:216–22.PubMedCrossRefGoogle Scholar
  67. 67.
    Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation. 2005;112:1945–52.PubMedCrossRefGoogle Scholar
  68. 68.
    Biscione F, Pignalberi C, Totteri A, Messina F, Altamura G. Cardiovascular effects of omega-3 free fatty acids. Curr Vasc Pharmacol. 2007;5:163–72.PubMedCrossRefGoogle Scholar
  69. 69.
    Das U. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, antiarrhythmic, antihypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis. 2008;7:37.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, Herse F, et al. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension. 2008;51:540–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Kenny D, Warltier DC, Pleuss JA, Hoffmann RG, Goodfriend TL, Egan BM. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol. 1992;70:1347–52.PubMedCrossRefGoogle Scholar
  72. 72.
    Harris WS, Rambjor GS, Windsor SL, Diederich D. n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr. 1997;65:459–64.PubMedGoogle Scholar
  73. 73.
    Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr. 2002;76:326–30.PubMedGoogle Scholar
  74. 74.
    Engler MM, Engler MB, Pierson DM, Molteni LB, Molteni A. Effects of docosahexaenoic acid on vascular pathology and reactivity in hypertension. Exp Biol Med (Maywood). 2003;228:299–307.Google Scholar
  75. 75.
    Rasmussen BM, Vessby B, Uusitupa M, Berglund L, Pedersen E, Riccardi G, et al. Effects of dietary saturated, monounsaturated, and n-3 fatty acids on blood pressure in healthy subjects. Am J Clin Nutr. 2006;83:221–6.PubMedGoogle Scholar
  76. 76.
    Cabo J, Alonso R, Mata P. Omega-3 fatty acids and blood pressure. Br J Nutr. 2012;107:S195–200.PubMedCrossRefGoogle Scholar
  77. 77.
    Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA. 2010;303(3):250–7.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Luchtman DW, Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology. 2013;64:550–65.PubMedCrossRefGoogle Scholar
  79. 79.
    Fedorova I, Hussein N, Baumann MH, Di Martino C, Salem N. An n-3 fatty acid deficiency impairs rat spatial learning in the barnes maze. Behav Neurosci. 2009;123:196–205.PubMedCrossRefGoogle Scholar
  80. 80.
    Yamamoto N, Saitoh M, Moriuchi A, Nomura M, Okuyama H. Effect of dietary alpha-linolenate/linoleate balance on brain lipid compositions and learning ability of rats. J Lipid Res. 1987;28:144–51.PubMedGoogle Scholar
  81. 81.
    Dyall SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. Neuromol Med. 2008;10:219–35.CrossRefGoogle Scholar
  82. 82.
    Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, et al. Low serum cholesteryl ester—docosahexaenoic acid levels in Alzheimer’s disease: a case-control study. Br J Nutr. 2003;89:483–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Lin PY, Chiu CC, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. J Clin Psychiatry. 2012;73:1245–54.PubMedCrossRefGoogle Scholar
  84. 84.
    Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res. 2012;56(7):1073–80.PubMedCrossRefGoogle Scholar
  85. 85.
    Shahzad K, Chokshi A, Schulze PC. Supplementation of glutamine and omega-3 polyunsaturated fatty acids as a novel therapeutic intervention targeting metabolic dysfunction and exercise intolerance in patients with heart failure. Curr Clin Pharmacol. 2011;6(4):288–94.PubMedCrossRefGoogle Scholar
  86. 86.
    Wu JH, Micha R, Imamura F, Pan A, Biggs ML, Ajaz O, et al. Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. Br J Nutr. 2012;107(2):S214–27.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Giacco R, Cuomo V, Vessby B, Uusitupa M, Hermansen K, Meyer BJ, et al. Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids? Nutr Metab Cardiovasc Dis. 2007;17(8):572–80.PubMedCrossRefGoogle Scholar
  88. 88.
    Griffin MD, Sanders TA, Davies IG, Morgan LM, Mill-ward DJ, Lewis F, et al. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45–70 y: the OPTILIP study. Am J Clin Nutr. 2006;84(6):1290–8.PubMedGoogle Scholar
  89. 89.
    Villegas R, Xiang YB, Elasy T, Li HL, Yang G, Cai H, et al. Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women. Am J Clin Nutr. 2011;94(2):543–51.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Kondo K, Morino K, Nishio Y, Kondo M, Nakao K, Nakagawa F, et al. A fish based diet intervention improves endothelial function in postmenopausal women with type 2 diabetes mellitus: a randomized crossover trial. Metabolism. 2014;63:930–40.PubMedCrossRefGoogle Scholar
  91. 91.
    Rizza S, Tesauro M, Cardillo C, Galli A, Iantorno M, Gigli F, et al. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis. 2009;206(2):569–74.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Djousse L, Gaziano JM, Buring JE, Lee IM. Dietary omega-3 fatty acids and fish consumption and risk of type 2 diabetes. Am J Clin Nutr. 2011;93(1):143–50.PubMedCrossRefGoogle Scholar
  93. 93.
    van Woudenbergh GJ, van Ballegooijen AJ, Kuijsten A, Sijbrands EJ, van Rooij FJ, Geleijnse JM, et al. Eating fish and risk of type 2 diabetes: a population-based, prospective follow-up study. Diabetes Care. 2009;32(11):2021–6.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Djousse L, Biggs ML, Lemaitre RN, King IB, Song X, Ix JH, et al. Plasma omega-3 fatty acids and incident diabetes in older adults. Am J Clin Nutr. 2011;94(2):527–33.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Akinkuolie AO, Ngwa JS, Meigs JB, Djousse L. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr. 2011;30(6):702–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Wallin A, Di Giuseppe D, Orsini N, Patel PS, Forouhi NG, Wolk A. Fish consumption, dietary long-chain n-3 fatty acids, and risk of type 2 diabetes: systematic review and meta-analysis of prospective studies. Diabetes Care. 2012;35(4):918–29.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Zheng JS, Huang T, Yang J, Fu YQ, Li D. Marine N-3 polyunsaturated fatty acids are inversely associated with risk of type 2 diabetes in Asians: a systematic review and meta-analysis. PLoS ONE. 2012;7(9):e44525.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Schubert R, Kitz R, Beermann C, Rose MA, Baer PC, Zielen S, et al. Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults. Nutrition. 2007;23:724–30.PubMedCrossRefGoogle Scholar
  99. 99.
    Bouwens M, van de Rest O, Dellschaft N, Bromhaar MG, de Groot LC, Geleijnse JM, et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr. 2009;90:415–24.PubMedCrossRefGoogle Scholar
  100. 100.
    Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis. 2009;204:476–82.PubMedCrossRefGoogle Scholar
  101. 101.
    Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, et al. Omega-3 fatty acid supplements improve the cardio-vascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol. 2009;64:321–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Connor WE. N-3 fatty acids from fish and fish oil: panacea or nostrum? Am J Clin Nutr. 2001;74:415–6.PubMedGoogle Scholar
  103. 103.
    Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Draper HH, editor. Advanced nutrition research. vol. 3. New York: Plenum Press; 1980. p. 1–22.Google Scholar
  104. 104.
    Kagawa Y, Nishizawa M, Suzuki M. Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. J Nutr Sci Vitaminol. 1982;28:441–53.PubMedCrossRefGoogle Scholar
  105. 105.
    Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296:1885–99.PubMedCrossRefGoogle Scholar
  106. 106.
    Harris WS, Mozaffarian D, Lefevre M, Toner CD, Colombo J, Cunnanes C, et al. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr. 2009;139:804S–19S.PubMedCrossRefGoogle Scholar
  107. 107.
    Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2008;337:a2931.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32:365–72.PubMedCrossRefGoogle Scholar
  109. 109.
    Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y et al., for the Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090–98.Google Scholar
  110. 110.
    Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369(9567):1090–8. Erratum in: Lancet 2007;370(9583):220.Google Scholar
  111. 111.
    Oikawa S, Yokoyama M, Origasa H, et al. for the JELIS Investigators, Japan. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008;200:135–40.Google Scholar
  112. 112.
    Sekikawa A, Kuller LH. Coronary heart disease mortality in the United States among black and white men 35–44 years old by state. CVD Prev. 1999;2:212–21.Google Scholar
  113. 113.
    Sekikawa A, Curb JD, Ueshima H, El-Saed A, Kadowaki T, Abbott RD, et al. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol. 2008;52(6):417–24.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57(2):193–200.PubMedCrossRefGoogle Scholar
  115. 115.
    Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the GruppoItaliano per lo Studio dellaSopravvivenzanell’InfartoMiocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897–903.PubMedCrossRefGoogle Scholar
  116. 116.
    GruppoItaliano per lo Studio dellaSopravvivenzanell’Infartomiocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354(9177):447–455. Erratum in: Lancet 2001;357(9256):642. Lancet 2007;369(9556):106.Google Scholar
  117. 117.
    Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. N-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the cardiovascular health study. Am J Clin Nutr. 2003;77(2):319–25.PubMedGoogle Scholar
  118. 118.
    Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Gissi-HF investigators, effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–30.PubMedCrossRefGoogle Scholar
  119. 119.
    Eritsland J, Arnesen H, Grønseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996;77:31–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Yamagishi K, Nettleton JA, Folsom AR. ARIC study investigators. plasma fatty acid composition and incident heart failure in middle—aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:965–74.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Strøm M, Halldorsson TI, Mortensen EL, Torp-Pedersen C, Sjurdur F. Fish, n-3 fatty acids, and cardiovascular diseases in women of reproductive age: a prospective study in a large national cohort. Hypertension. 2012;59:36–43.PubMedCrossRefGoogle Scholar
  122. 122.
    Streppel MT, Ocké MC, Boshuizen HC, Kok FJ, Kromhout D. Long-term fish consumption and n-3 fatty acid intake in relation to (sudden) coronary heart disease death: the Zutphen study. Eur Heart J. 2008;16:2024–30.CrossRefGoogle Scholar
  123. 123.
    Abuissa H, O’Keefe JH, Bybee KA. Statins as antiarrhythmics: a systematic review part II: effects on risk of ventricular arrhythmias. Clin Cardiol. 2009;32(10):549–52.PubMedCrossRefGoogle Scholar
  124. 124.
    Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5:808–18.PubMedCrossRefGoogle Scholar
  125. 125.
    Harris WS, Shearer GC. Omega-6 fatty acids and cardiovascular disease: friend, not foe? Circulation. 2014;130:1562–4.PubMedCrossRefGoogle Scholar
  126. 126.
    Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RN, Wever EF, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on Omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA;295(22):2613–9.Google Scholar
  127. 127.
    Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152–9.PubMedCrossRefGoogle Scholar
  128. 128.
    Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. N–3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015–26.PubMedCrossRefGoogle Scholar
  129. 129.
    Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024–33.PubMedCrossRefGoogle Scholar
  130. 130.
    Lewis EJH. Omega-3 fatty acid supplementation and cardiovascular disease events [letter]. JAMA. 2013;309(1):27.PubMedCrossRefGoogle Scholar
  131. 131.
    Vlachopoulos C, Richter D, Stefanadis C. Omega-3 fatty acid supplementation and cardiovascular disease events. JAMA. 2013;309(1):28.PubMedCrossRefGoogle Scholar
  132. 132.
    Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Svensson M, Schmidt EB, Jrgensen KA, Christensen JH, OPACH Study Group. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol. 2006;1(4):780–6.PubMedCrossRefGoogle Scholar
  134. 134.
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5) supplement 3:S112–9.Google Scholar
  135. 135.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRefGoogle Scholar
  136. 136.
    Lee SM, An WS. Cardioprotective effects of ω-3 PUFAs in chronic kidney disease. Biomed Res Int. 2013;2013:712949.PubMedPubMedCentralGoogle Scholar
  137. 137.
    Katan MB, Zock PL, Mensink RP. Dietary oils, serum lipoproteins, and coronary heart disease. Am J Clin Nutr. 1995;61(6):S1368–73.Google Scholar
  138. 138.
    Astrup A, Hill JO, Saris WHM, Taubes G. Dietary fat: at the heart of the matter. Science. 2001;293(5531):801–4.PubMedGoogle Scholar
  139. 139.
    An WS, Lee SM, Son YK, Kim SE, Kim KH, Han JY, et al. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukot Essent Fatty Acids. 2012;86(1–2):29–34.PubMedCrossRefGoogle Scholar
  140. 140.
    An WS, Lee SM, Son YK, Kim SE, Kim HK, Han JY, et al. Omega-3 fatty acid supplementation increases 1, 25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. Nutr Res. 2012;32(7):495–502.PubMedCrossRefGoogle Scholar
  141. 141.
    Riediger ND, Othman RA, Suh M, Moghadasian MH. A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc. 2009;109(4):668–79.PubMedCrossRefGoogle Scholar
  142. 142.
    Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001;(12)1549–57.Google Scholar
  143. 143.
    Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140(1):9–17.PubMedCrossRefGoogle Scholar
  144. 144.
    Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108(2):155–60.PubMedCrossRefGoogle Scholar
  145. 145.
    Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, Sobajic SS, Djuricic I, Maletic R, et al. Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology. 2007;12(4):331–6.PubMedCrossRefGoogle Scholar
  146. 146.
    Hassan KS, Hassan KS, Hijazi EG, Khazim KO. Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren Fail. 2010;32(9):1031–5.PubMedCrossRefGoogle Scholar
  147. 147.
    An WS, Kim HJ, Cho KH, Vaziri ND. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol. 2009;297(4):F895–903.PubMedCrossRefGoogle Scholar
  148. 148.
    Block RC, Harris WS, Reid KJ, Spertus JA. Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? Am Heart J. 2008;156(6):1117–23.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Paganelli JM, Maixent JM, Duran MJ, Parhizgar R, Pieroni G, Sennoune S. Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease. Int J Cardiol. 2001;78(1):27–32.PubMedCrossRefGoogle Scholar
  150. 150.
    An WS, Kim SE, Kim KH, Lee S, Park Y, Kim HJ, et al. Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients. J Ren Nutr. 2009;19(4):267–74.PubMedCrossRefGoogle Scholar
  151. 151.
    Egan BM, Lu G, Greene EL. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids. 1999;60(5–6):411–20.PubMedCrossRefGoogle Scholar
  152. 152.
    Lu G, Greene EL, Nagai T, Egan BM. Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells. Hypertension. 1998;32(6):1003–10.PubMedCrossRefGoogle Scholar
  153. 153.
    Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19(10):1045–52.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Shobeiri N, Pang J, Adams MA, Holden RM. Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. J Hypertens. 2013;31(1):160–8.PubMedCrossRefGoogle Scholar
  155. 155.
    Nishizawa H, Hamazaki K, Hamazaki T, Fujioka S, Sawazaki S. The relationship between tissue RBC n-3 fatty acids and pulse wave velocity. In Vivo. 2006;20(2):307–10.PubMedGoogle Scholar
  156. 156.
    Szweras M, Liu D, Partridge EA, Pawling J, Sukhu B, Clokie C, et al. Alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morpho-genetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem. 2002;277(22):19991–7.PubMedCrossRefGoogle Scholar
  157. 157.
    Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11.PubMedCrossRefGoogle Scholar
  158. 158.
    Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629–37.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Artaza JN, Mehrotra R, Norris KC. Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol. 2009;4(9):1515–22.PubMedCrossRefGoogle Scholar
  160. 160.
    Harris WS, Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39(1):212–20.PubMedCrossRefGoogle Scholar
  161. 161.
    Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, et al. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation. 2004;110:1645–9.PubMedCrossRefGoogle Scholar
  162. 162.
    Metcalf RG, James MJ, Gibson RA, Edwards JR, Stubberfield J, Stuklis R, et al. Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr. 2007;85:1222–8.PubMedGoogle Scholar
  163. 163.
    Aarsetøy H, Pönitz HV, Nilsen OB, Grundt H, Harris WS, Nilsen DW. Low levels of cellular omega-3 increase the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation. 2008;78:258–64.PubMedCrossRefGoogle Scholar
  164. 164.
    Aarsetoey H, Aarsetoey R, Lindner T, Staines H, Harris WS, Nilsen DW. Low levels of the omega-3 index are associated with sudden cardiac arrest and remain stable in survivors in the subacute phase. Lipids. 2011;46:151–61.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274:1363–7.PubMedCrossRefGoogle Scholar
  166. 166.
    Aarsetoey H, Ponitz V, Grundt H, Staines H, Harris WS, Nilsen DW. (n-3) Fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome. J Nutr. 2009;139:507–13.PubMedCrossRefGoogle Scholar
  167. 167.
    Von Schacky C. Omega-3 fatty acids vs. cardiac disease-the contribution of the omega-3 index. Cell Mol Biol (Noisy-le-grand). 2010;56:93–101.Google Scholar
  168. 168.
    Harris WS, Kris-Etherton PM, Harris KA. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep. 2008;10:503–9.PubMedCrossRefGoogle Scholar
  169. 169.
    Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151–2.PubMedCrossRefGoogle Scholar
  170. 170.
    Simopoulos AP, Leaf A, Salem N Jr. Workshop statement on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2000;63:119–21.PubMedCrossRefGoogle Scholar
  171. 171.
    Fares H, Lavie CJ, DiNicolantonio JJ, O’Keefe JH, Milani RV. Omega-3 fatty acids: a growing ocean of choices. Curr Atheroscler Rep. 2014;16:389.PubMedCrossRefGoogle Scholar
  172. 172.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354–67.PubMedCrossRefGoogle Scholar
  173. 173.
    Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial). Am J Cardiol. 2011;108:682–90.PubMedCrossRefGoogle Scholar
  174. 174.
    Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2010;10:24.PubMedPubMedCentralCrossRefGoogle Scholar
  175. 175.
    Chalupka S. Omega-3 polyunsaturated fatty acid in primary and secondary cardiovascular disease prevention. AAOHN J. 2009;57(11):480.PubMedGoogle Scholar
  176. 176.
    Park K, Mozaffarian D. Omega-3 fatty acids, mercury, and selenium in fish and the risk of cardiovascular diseases. Curr Atheroscler Rep. 2010;12(6):414–22.PubMedCrossRefGoogle Scholar
  177. 177.
    Judge MP, Harel O, Lammi-Keefe CJ. Maternal consumption of a docosahexaenoic acid-containing functional food during pregnancy: benefit for infant performance on problem-solving but not on recognition memory tasks at age 9 mo. Am J ClinNutr. 2007;85:1572–7.Google Scholar
  178. 178.
    Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42:174–81.PubMedCrossRefGoogle Scholar
  179. 179.
    Bernardi JR, de Escobar RS, Ferreira CF, Sileira PP. Fetal and neonatal levels of omega-3: effects on neurodevelopment, nutrition, and growth. Sci World J. 2012;2012:202473.Google Scholar
  180. 180.
    Crawford MA, Costeloe K, Ghebremeskel K, Phylactos A, Skirvin L, Stacey F. Are deficits of arachidonic and docosahexaenoic acids responsible for the neural and vascular complications of preterm babies? Am J Clin Nutr. 1997;66(4):1032S–41S.PubMedGoogle Scholar
  181. 181.
    DiNicolantonio JJ, Niazi AK, O’Keefe JH, Lavie CJ. Explaining the recent fish oil trial “failures”. J Glycomics Lipidomics. 2013;3(1):e112.Google Scholar
  182. 182.
    Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care. 2000;23(9):1407–15.PubMedCrossRefGoogle Scholar
  183. 183.
    Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HAW. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia. 2007;50(8):1593–602.PubMedCrossRefGoogle Scholar
  184. 184.
    Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation. 2003;107(14):1852–7.PubMedCrossRefGoogle Scholar
  185. 185.
    Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc. 2005;105(3):428–40.PubMedCrossRefGoogle Scholar
  186. 186.
    Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20(8):1493–9.PubMedCrossRefGoogle Scholar
  187. 187.
    Campos H, Baylin A, Willett WC. Alpha-linolenic acid and risk of nonfatal acute myocardial infarction. Circulation. 2008;118:339–45.PubMedPubMedCentralCrossRefGoogle Scholar
  188. 188.
    Tillander V, Bjørndal B, Bohov P, Burri L, Skorve J, Berge RK, et al. Fish oil and krill oil supplementations differentially regulate lipid catabolic and synthetic pathways in mice. Nutr Metab (Lond). 2014;11:20.CrossRefGoogle Scholar
  189. 189.
    Kumar S, Sutherland F, Morton JB, Lee G, Morgan J, Wong J, et al. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart Rhythm. 2012;9(4):483–91.PubMedCrossRefGoogle Scholar
  190. 190.
    Patel D, Shaheen M, Venkatraman P, Armaganijan L, Sanchez JE, et al. Omega-3 polyunsaturated fatty acid supplementation reduced atrial fibrillation recurrence after pulmonary vein antrum isolation. Indian Pacing Electrophysiol J. 2009;9:292–8.PubMedPubMedCentralGoogle Scholar
  191. 191.
    Bairati I, Roy L, Meyer F. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation. 1992;85:950–6.PubMedCrossRefGoogle Scholar
  192. 192.
    Maresta A, Balduccelli M, Varani E, Marzilli M, Galli C, Heiman F, ESPRIT Investigators, et al. Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT). Am Heart J. 2002;143:E5.PubMedCrossRefGoogle Scholar
  193. 193.
    Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005;45:1723–8.PubMedCrossRefGoogle Scholar
  194. 194.
    Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, et al. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg. 2009;57:276–80.PubMedCrossRefGoogle Scholar
  195. 195.
    Yamagishi K, Iso H, Date C, Fukui M, Wakai K, Kikuchi S, et al. Japan Collaborative Cohort Study for Evaluation of Cancer Risk Study Group. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women: the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol 2008;52:988–96.Google Scholar
  196. 196.
    Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–26.PubMedCrossRefGoogle Scholar
  197. 197.
    Brouwer IA, Raitt MH, Dullemeijer C, Kraemer DF, Zock PL, Morris C, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J. 2009;30:820–6.PubMedPubMedCentralCrossRefGoogle Scholar
  198. 198.
    Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010;304:2363–72.PubMedCrossRefGoogle Scholar
  199. 199.
    Reis GJ, Boucher TM, Sipperly ME, Silverman DI, McCabe CH, Baim DS, et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet. 1989;2(8656):177–81.PubMedCrossRefGoogle Scholar
  200. 200.
    Bridgewater B, Saravanan P, O’Neill SC, West AL, Calder PC, Davidson NC, et al. Omega-3fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythmia Electrophysiol. 2010;3:46–53.CrossRefGoogle Scholar
  201. 201.
    Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA, et al. Effect of dietary fish oil on atrial fibrillation after cardiac surgery. Am J Cardiol. 2011;108:851–6.PubMedCrossRefGoogle Scholar
  202. 202.
    Dijkstra SC, Brouwer IA, van Rooij FJ, Hoffman A, Witteman JC, Jeleijnse JM. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the rotterdam study. Eur J Heart Fail. 2009;11:922–8.PubMedCrossRefGoogle Scholar
  203. 203.
    Belin RJ, Greenland P, Martin L, Oberman A, Tinker L, Robinson J, et al. Fish intake and the risk of incident heart failure: the Women’s Health Initiative. Circ Heart Fail. 2011;4:404–13.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Endocrine and Diabetes UnitChristian Medical College and HospitalLudhianaIndia

Personalised recommendations